New drug shows promise for stem cell transplant complication

NCT ID NCT04198922

Ongoing Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called acalabrutinib in 51 adults with moderate to severe chronic graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to see if the drug can control the disease when steroids have stopped working. Participants take the drug and are monitored for response and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM RECURRENT MODERATE-SEVERE CHRONIC GRAFT VERSUS HOST DISEASE

Contacts and locations

Show contact details

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.